Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC

Arrivent Biopharma

related news
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NASDAQ

July 14 2026
Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Reuters

April 18 2026

Get In Touch

Contact Us